Women’s Health Company Freya Biosciences Announces Key $10.4 Million Strategic Investment
- Strategic investment from the Bill & Melinda Gates Foundation with additional investment from EIFO brings the total to $11.8 million
- The new investment extends Series A investment to about $50 million
- Funds will be used to expand Freya’s DYSCOVERTM platform to identify and develop microbial immunotherapies to treat bacterial vaginosis and prevent pre-term birth
COPENHAGEN, Denmark and BOSTON, Nov. 19, 2024 /PRNewswire/ — Freya Biosciences (Freya or the Company), a transatlantic biotech company specializing in women’s health, today announces a $10.4 million strategic investment from the Bill & Melinda Gates Foundation (the foundation) with $1.4 million additional financing from current investor Export and Investment Fund of Denmark (EIFO).
